Skip to main content

Chronic Subdural Hematoma

0
Pipeline Programs
3
Companies
4
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Scientia Vascular
Scientia VascularUT - West Valley City
1 program
Matched pair Aristotle 14 guidewire and Plato 17 microcatheterN/A1 trial
Active Trials
NCT07324551Recruiting100Est. Jul 2029
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)N/A1 trial
Active Trials
NCT06181994Recruiting5,000Est. Aug 2026
BALT
BALTCA - Irvine
1 program
SQUIDN/A2 trials
Active Trials
NCT07255508Not Yet Recruiting100Est. Nov 2027
NCT04410146Completed319Est. May 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Scientia VascularMatched pair Aristotle 14 guidewire and Plato 17 microcatheter
BALTSQUID
Oregon TherapeuticsMiddle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)
BALTSQUID

Clinical Trials (4)

Total enrollment: 5,519 patients across 4 trials

NCT07324551Scientia VascularMatched pair Aristotle 14 guidewire and Plato 17 microcatheter

Microfabricated Microcatheter Advantages in Middle Meningeal Artery Embolization: an Early Experience at a Single Center

Start: Nov 2025Est. completion: Jul 2029100 patients
N/ARecruiting
NCT07255508BALTSQUID

Efficacy of Prostatic Arteries Embolization Using SQUIDPERI

Start: Nov 2025Est. completion: Nov 2027100 patients
N/ANot Yet Recruiting
NCT06181994Oregon TherapeuticsMiddle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)

Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)

Start: Dec 2023Est. completion: Aug 20265,000 patients
N/ARecruiting
NCT04410146BALTSQUID

The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma (STEM)

Start: Nov 2020Est. completion: May 2024319 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 5,519 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.